Calamos Advisors LLC Decreases Holdings in Guardian Pharmacy Services, Inc. $GRDN

Calamos Advisors LLC trimmed its position in Guardian Pharmacy Services, Inc. (NYSE:GRDN) by 30.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,949 shares of the company’s stock after selling 11,970 shares during the period. Calamos Advisors LLC’s holdings in Guardian Pharmacy Services were worth $596,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Parkside Financial Bank & Trust purchased a new stake in shares of Guardian Pharmacy Services during the 2nd quarter valued at $41,000. Police & Firemen s Retirement System of New Jersey increased its position in Guardian Pharmacy Services by 76.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 2,444 shares of the company’s stock valued at $52,000 after buying an additional 1,062 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Guardian Pharmacy Services during the 2nd quarter valued at about $75,000. Meeder Asset Management Inc. purchased a new stake in Guardian Pharmacy Services in the first quarter valued at about $88,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Guardian Pharmacy Services in the first quarter worth about $233,000.

Guardian Pharmacy Services Trading Down 4.6%

Shares of NYSE:GRDN opened at $29.03 on Friday. Guardian Pharmacy Services, Inc. has a twelve month low of $17.78 and a twelve month high of $37.43. The company has a market cap of $1.84 billion, a PE ratio of 46.08 and a beta of 0.96. The company’s 50 day moving average is $27.04 and its 200 day moving average is $24.10.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.24 by $0.01. The business had revenue of $377.43 million during the quarter, compared to analysts’ expectations of $381.16 million. Guardian Pharmacy Services had a net margin of 2.90% and a return on equity of 30.29%. Guardian Pharmacy Services has set its FY 2025 guidance at EPS. Equities research analysts predict that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Guardian Pharmacy Services from a “sell (d+)” rating to a “hold (c)” rating in a report on Tuesday. Wall Street Zen downgraded shares of Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 9th. Truist Financial upped their price target on shares of Guardian Pharmacy Services from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Friday. Finally, Oppenheimer began coverage on shares of Guardian Pharmacy Services in a research note on Friday, October 10th. They set an “outperform” rating and a $30.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.67.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.